arimidex question

[phatkid77]

so i was thinking, since my E2 is 66 or so, and arimidex is studied to lower female estrogen by 80% and males by no more than 50%....

my E2 would then hit 33 or so.... for people with real high estrogen, would femera or aromasin be better..?

why do the most bodybuilders prefer aromasin over EVERYTHING...? while HRT docs in the states like adex?

phats

 

[AWN2004]

Aromasin -

Lipids dont get torched

Studies show an increase in IGF-1 where most others can lower it.

It's strong...really damn strong. You could cut the pills in half and use one half every third day in some cases and be good to go.

Why do American doctors push A-Dex like crazy? AstraZeneca giving major kick backs to the MD's writing the scripts might have something to do with it. Its all about money. Forget about the fact that if your doctor is writing you a script for that drug he most likely knows you are taking some sort of androgen. That coupled with the diets most bodybuilders have is a potential recipie for disaster lipid wise. Ask for Aromasin. Even if it costs you more out of pocket your heart and arteries will thank you in the long run.

 

[phatkid77]

any links to the studies showing IGF-1 levels?? i wish my mother still had an active script...fack
are lipids a big concern at .25mg EOD?

phats
this shows IGF unaffected
http://jcem.endojournals.org/cgi/co...NDEX=30&sortspec=relevance&resourcetype=HWCIT

and yes, im on HRT, looking to lower estrogens...

 

[Phidias]

Why do American doctors push A-Dex like crazy? AstraZeneca giving major kick backs to the MD's writing the scripts might have something to do with it. Its all about money.

Bingo! And it works the same over here in Europe... one of my best friend is a doc (has a huge clientele since he's also a gynecollogist) and believe me when I say to you he NEVER pays for his holydays...

Don't really know about the igf-1 thing, but from bloodwork I can indeed tell you that mild to high dose A-dex (up to 1 tab a day) doesn't help with hdl at all...

 

[phatkid77]

1 tab a day is pretty high...

just found this

Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. [email protected]

BACKGROUND: The newer generation, nonsteroidal aromatase inhibitors (AIs) anastrozole and letrozole have shown superior efficacy compared with tamoxifen as first-line treatments and compared with megestrol acetate as second-line therapy in postmenopausal women with advanced breast carcinoma. In an open-label, Phase II trial, it was reported that exemestane showed numerical superiority compared with tamoxifen for objective response and clinical benefit. Because these agents ultimately may be administered for periods of up to 5 years in the adjuvant setting, it is of increasing importance to assess their tolerability and pharmacologic profiles. METHODS: In the absence of data from direct clinical comparisons, the published literature was reviewed for the clinical pharmacology, pharmacokinetic characteristics, and selectivity profiles of anastrozole, letrozole, and exemestane. RESULTS: At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) were 41-48 hours, 2-4 days, and 27 hours, respectively. The time to steady-state plasma levels was 7 days for both anastrozole and exemestane and 60 days for letrozole. Androgenic side effects have been reported only with exemestane. Anastrozole treatment had no impact on plasma lipid levels, whereas both letrozole and exemestane had an unfavorable effect on plasma lipid levels. In indirect comparisons, anastrozole showed the highest degree of selectivity compared with letrozole and exemestane in terms of a lack of effect on adrenosteroidogenesis. CONCLUSIONS: All three AIs demonstrated clinical efficacy over preexisting treatments. However, there were differences in terms of pharmacokinetics and effects on lipid levels and adrenosteroidogenesis. The long-term clinical significance of these differences remains to be elucidated. Copyright 2002 American Cancer Society.